Literature DB >> 16478641

Eve-3: a liver enriched suppressor of Ras/MAPK signaling.

James A J King1, Niall M Corcoran, Giovanna M D'Abaco, Andrew F Straffon, Craig T Smith, Carole L C Poon, Michael Buchert, Stacey I, Nathan E Hall, Peter Lock, Christopher M Hovens.   

Abstract

BACKGROUND/AIMS: The developed liver is able to tightly control cellular proliferation, rapidly switching from quiescence to growth in response to specific stimuli. This suggests that growth inhibitors may be involved in the control of liver growth. We analyzed the role of the Spred-family of growth inhibitors in the liver.
METHODS: We screened human EST databases for Spred-related sequences. Clones were isolated, sequenced, epitope-tagged and expressed. Subcellular localization of clones were determined and their effects on cellular signaling pathways analysed using specific antibodies. Cell cycle progression assays and protein interaction studies were initiated. Organ distribution of transcripts and their expression throughout liver development and in primary hepatocytes were recorded.
RESULTS: We have identified a new, liver-restricted protein, Eve-3, containing a single Ena Vasp homology (EVH1) domain that can potently block activation of the Ras/MAPK pathway. Eve-3 is specific in inhibiting the Ras/MAPK pathway. Eve-3 can block serum-mediated cell cycle progression and its expression is highly regulated during liver development.
CONCLUSIONS: The liver is the only organ that can regulate its growth and mass. Eve-3 may act as an inhibitor of proliferation pathways in the mature liver and be involved in modulating the unique regenerative capacity of this organ.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16478641     DOI: 10.1016/j.jhep.2005.10.031

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  9 in total

1.  Identification of SPRED2 (sprouty-related protein with EVH1 domain 2) as a negative regulator of the hypothalamic-pituitary-adrenal axis.

Authors:  Melanie Ullrich; Karin Bundschu; Peter M Benz; Marco Abesser; Ruth Freudinger; Tobias Fischer; Julia Ullrich; Thomas Renné; Ulrich Walter; Kai Schuh
Journal:  J Biol Chem       Date:  2011-01-03       Impact factor: 5.157

2.  A shared molecular mechanism underlies the human rasopathies Legius syndrome and Neurofibromatosis-1.

Authors:  Irma B Stowe; Ellen L Mercado; Timothy R Stowe; Erika L Bell; Juan A Oses-Prieto; Hilda Hernández; Alma L Burlingame; Frank McCormick
Journal:  Genes Dev       Date:  2012-07-01       Impact factor: 11.361

3.  Pathogenesis and prognosis of primary oral squamous cell carcinoma based on microRNAs target genes: a systems biology approach.

Authors:  Amir Taherkhani; Shahab Shahmoradi Dehto; Shokoofeh Jamshidi; Setareh Shojaei
Journal:  Genomics Inform       Date:  2022-09-30

Review 4.  Nonredundant functions for Ras GTPase-activating proteins in tissue homeostasis.

Authors:  Philip D King; Beth A Lubeck; Philip E Lapinski
Journal:  Sci Signal       Date:  2013-02-26       Impact factor: 8.192

5.  SPRED1 Interferes with K-ras but Not H-ras Membrane Anchorage and Signaling.

Authors:  Elina Siljamäki; Daniel Abankwa
Journal:  Mol Cell Biol       Date:  2016-09-26       Impact factor: 4.272

Review 6.  Feedback regulation of RTK signaling in development.

Authors:  Cynthia L Neben; Megan Lo; Natalia Jura; Ophir D Klein
Journal:  Dev Biol       Date:  2017-10-26       Impact factor: 3.582

7.  Oxidized low-density lipoprotein is a common risk factor for cardiovascular diseases and gastroenterological cancers via epigenomical regulation of microRNA-210.

Authors:  Ku-Chung Chen; Yi-Chu Liao; Jaw-Yuan Wang; Ying-Chu Lin; Chung-Ho Chen; Suh-Hang Hank Juo
Journal:  Oncotarget       Date:  2015-09-15

Review 8.  Progress in experimental research on SPRED protein family.

Authors:  Jian Gong; Zhangren Yan; Qiao Liu
Journal:  J Int Med Res       Date:  2020-08       Impact factor: 1.671

9.  Spred-3 mutation and Ras/Raf/MAPK activation confer acquired resistance to EGFR tyrosine kinase inhibitor in an EGFR mutated NSCLC cell line.

Authors:  Zhiyong He; Fusheng Gong; Jinrong Liao; Qiang Wang; Ying Su; Chao Chen; Jinghui Lin; Ren-Jang Lin
Journal:  Transl Cancer Res       Date:  2020-04       Impact factor: 1.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.